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Editorial
The antibiotics have represented a great revolution for humankind, 
the development after the World War II of a magic bullet (the antibiotic 
molecule), as imagined by Paul Erlich, the pioneer of chemotherapy, 
with the property to kill or inhibit the growth of microorganisms by 
hitting the microbial structures with low toxicity for host cells and 
tissues, has determined a new era in the treatment and prophylaxisis of 
infectious disease and in the quality of human life. 
However, starting from ’50 of last century up to recent decades 
and currently, a large number of antibiotics, due to the emergence of 
multidrug-resistant bacterial strains (both Gram-negative and Gram-
positive), have become scarcely effective and not-useful. It is estimated 
that drug-resistant strains of bacteria are responsible for 5,000 deaths a 
year in the UK and 25,000 deaths a year in Europe. The World Health 
Organization, in the recent (2014) report on antimicrobial resistance in 
common bacterial pathogens, states that a post-antibiotic era is a close 
possibility for the 21st century [http://www.who.int/drugresistance/
documents/surveillancereport/en/]. Moreover, there is a lack of 
investments by pharmaceutical companies in the development of new 
antibiotics, but new antimicrobials for counteracting the pathogens 
are needed. This scenario has to stimulate the research of alternative 
strategies to conventional antibiotics. How could we imagine the 
antibiotic of future, which additional characteristics should it have? 
Starting from a good selectivity index (that is the ratio between toxic 
dose for the host and efficient dose against microbial cells), other 
important properties to obtain a “smart bullet” will be needed: the 
ability to hit pathogens without killing beneficial microbiota; a low 
selectivity pressure to promote the rise in antibiotic-resistance strains; 
the property to tackle natural form of resistance like multi-stratified 
microbial population growing on surfaces, the so-called biofilms; 
the capacity to eliminate “dormant” cells, that is microbial cells 
metabolically inert and for this naturally resistant to current antibiotics. 
The first two objectives could be obtained throw the use of anti-
pathogenic agents. Over the last decade, many studies focused on agents 
that target the virulence of pathogens without killing or inhibiting the 
growth of microorganisms and therefore with limited selective pressure 
to promote the antibiotic resistance development [1,2]. A fundamental 
step of Gram-positive and Gram-negative pathogenesis is the bacterial 
adhesion to the host tissue involving a direct and a specific interaction 
between bacterial surface molecules and host ligands. Interfere with 
adhesion, the first step of pathogenesis, could be an efficient way to 
prevent or treat infections. The adhesion is a fundamental step for 
microbial colonization and infection and through it the pathogens also 
avoid to be mechanically removed from the host [3].
Gram-positive and Gram-negative pathogens adhere to the 
host tissues through filamentous organelles known as pili [4,5]. The 
pili function on initial bacterial attachment, invasion and biofilm 
formation, has been mainly studied for Gram-negative bacteria [5]. 
Some new agents, known as pilicides, have been synthesized to target 
the chaperone–subunit interaction [6] and the chaperone interaction 
with a protein involved in the biogenesis of the pili in Gram-negative 
known as fimbrial usher protein [7]. Uropathogenic Escherichia coli 
(UPEC) is the major aetiological agent of Urinary Tract Infections 
(UTIs) and is often studied as model of Gram-negative pathogen for 
the development of pilicides compounds.
There are many works on the synthesis of pilicides [6,7], in a recent 
article on this subject, it has been reported the synthesis of N-(4-chloro-
phenyl)-2-{5-[4-(pyrrolidine-1-sulfonyl)-phenyl]-[1,3,4]oxadiazol-
2-yl sulfanyl}-acetamide as inhibitor of the assembly of type 1 pili 
interfering with the subunit incorporation cycle of the chaperone–
usher pathway [8].
Similar structural motifs of pilin components has been found in 
an important family of Gram-positive surface proteins, the Microbial 
Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs), able to recognize host’s extracellular matrix proteins, 
such as fibrinogen, fibronectin, and collagen [4,9].
If we consider the important part played by MSCRAMMs in the 
first step of Gram-positive pathogenesis and of biofilm formation, we 
believe that new anti-virulence agents could be developed by using as a 
target the enzyme responsible of linking such proteins to cell wall, that 
is the Sortase A (SrtA), rather than any single surface protein involved 
in the mechanism of virulence [10]. The SrtA is a membrane-bound 
cysteine transpeptidase that is responsible, in Gram-positive bacteria, 
for the covalent anchoring of surface proteins to bacterial cell wall.
SrtA inhibitors can be classified into three groups: natural 
compounds, peptides and synthetic small molecules. Natural 
compounds with SrtA inhibitory activity are obtained principally from 
plants as Fritillaria verticillata [11], Rhus verniciflua [12], Curcuma 
longa L [13-15], Coptis chinensis [16], Sophora flavescens [17] and from 
marine invertebrates like the sponges Spongosorites sp [18], Aaptos 
aaptos [19], Sceptrella sp [20], Coscinoderma sp [21] and like the 
ascidian Synoicum sp [22,23]. 
The first peptides described as SrtA inhibitors were the peptidyl-
diazomethane and peptidyl-chloromethane analogues, Cbz 
(benzyloxycarbonyl)-Leu-Pro-Ala-Thr-CHN2 and Cbz-Leu-Pro-
Ala-Thr-CH2Cl which found to act as time-dependent irreversible 
inhibitors of recombinant sortase (SrtA∆N). The inhibitor sequences 
mimic the substrate recognition motif of the SrtA (-Leu-Pro-Xaa-
Thr-Gly-) with the difference that the scissile amide bond between 
threonine and glycine residues was replaced with a diazoketone or 
chloromethyl ketone group, groups able to alkylate the Cys 184 of the 
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enzyme active site [24]. Peptide acting as irreversible inhibitor of SrtA 
was obtained by Connolly et al. replacing the scissile Thr-Gly in the 
substrate recognition motif of SrtA with a vinyl sulfone group (C=C-
SO2Ph) [25].
Regarding synthetic small molecules the most representative were 
obtained via High-Throughput Screening by Suree et al. that described 
new derivatives belonging to the three chemical classes of rhodanines, 
pyridazinones and pyrazolethiones with SrtA IC50 values, for the 
most active molecules, of 3.7 μM, 0.20 μM and 0.30 μM, respectively. 
These molecules probably act on the enzyme through a thiol-disulfide 
exchange reaction with Cys 184 [26].
Other cell surface molecules in Gram-positive bacteria, involved 
in the adhesion process, without cell wall anchorage, are non-
proteinaceous adhesins like Wall Teichoic (WTA) and lipoteichoic 
acids. Since WTAs are required for host infection and play important 
role in biofilm formation, it has been suggested that they are important 
virulence factors required for the estabilishment and spread of infection 
in a host. Therefore, the enzymes involved in WTAs biosynthesis can 
be considered as good targets for novel antimicrobials that interfere 
with Gram-positive pathogenic process. One possible target is the 
WTA biosynthetic pathway because strains of S. aureus and B. subtilis 
mutants in WTAs are not able to colonize the host tissue and show 
a greatly diminished ability to establish infection in animal models 
[27,28].
Current antibiotics can be efficacious against planktonic (free 
living) pathogens but are poorly effective against bacteria growing 
as biofilms. Biofilms structured bacteria develop multifactorial 
mechanisms of antibiotic-resistance and one of the most important 
factor of tolerance is the slow growth and low metabolic activity of 
bacterial cells (dormant cells) in the internal layer of community, so they 
are intrinsically resistant to current antibiotics, which target dividing 
and metabolically active cells, and represent a reservoir for recurrent 
infections. The Antimicrobial Peptides (AMPs) [29] generally defined 
as cationic, amphipathic peptides, with no more than 50 amino acids, 
are very promising agents in the struggle against pathogenic biofilms, 
in fact they permeabilize and form pores within the cytoplasmatic 
membranes, so they can act on slow-growing or even non growing 
bacteria that exhibited a reduced susceptibility to many antibiotics. The 
AMPs also have a high potential for interfering with biofilm formation, 
in fact they could minimize initial adhesion of microbial cells to abiotic 
surfaces (medical devices etc.) by altering the adhesive features, or by 
inhibiting quorum-sensing, that is the communication system used 
by many pathogens to control collective behaviours, such as virulence 
factors production and biofilm formation.
There are many gaps of knowledge in the research of anti-virulence 
drugs, for example, the lack of assessment of the efficacy of most SrtA 
inhibitors by using in vitro or in vivo models of infections. Attenuation 
of virulence as antimicrobial strategy needs a good host immune 
defence for bacterial clearance, so immune-compromised patients 
could not be treated. That is a point of weakness of anti-virulence 
approach and further studies to improve the pharmaceutical potential 
of anti-virulence agents are needed. The possibility of using novel anti-
virulence agents in combination with AMPs that have also immune 
modulatory functions [30], could contribute to overcoming the 
above mentioned point of weakness, and make this strategy effective 
to combat the developing risk of pathogens that current antibiotics 
cannot defeat. 
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